Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kazuhiro Takahashi"'
Autor:
Taizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Yusuke Yano, Kazuki Nishimura, Keita Nakamori, Yuya Fujiwara, Tomohisa Matsunaga, Takeshi Tsutsumi, Takuya Tsujino, Ryoichi Maenosono, Yuki Yoshikawa, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Hajime Hirano, Hayahito Nomi, Kiyoshi Takahara, Teruo Inamoto, Shin Egawa, Haruhito Azuma
Publikováno v:
Cancers, Vol 13, Iss 14, p 3554 (2021)
Pembrolizumab has emerged as the new standard of care in patients with platinum-refractory metastatic urothelial carcinoma (mUC), whereas the optimal risk stratification to predict survival outcomes is still controversial. We examined a risk model fo
Externí odkaz:
https://doaj.org/article/c31800e5802843c0a9fc9c017980d50f
Autor:
Taizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Kazuki Nishimura, Keita Nakamori, Yuya Fujiwara, Tomohisa Matsunaga, Takeshi Tsutsumi, Takuya Tsujino, Ryoichi Maenosono, Yuki Yoshikawa, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Naokazu Ibuki, Hajime Hirano, Hayahito Nomi, Kiyoshi Takahara, Teruo Inamoto, Shin Egawa, Haruhito Azuma
Publikováno v:
Cancers, Vol 13, Iss 3, p 526 (2021)
The identification of early or primary resistance to androgen signaling inhibitors (ASIs) is of great value for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the predictive value of prostate-specific a
Externí odkaz:
https://doaj.org/article/316c1784509244e188c106dec81ba88f
Autor:
Eiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Kazuhiro Takahashi, Takeaki Satoh, Toshimasa Koyanagi, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Masaki Kato, Shinji Shimoda, Jun Hayashi
Publikováno v:
Cancers, Vol 12, Iss 9, p 2602 (2020)
Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients with chronic hepatitis C (CHC) following hepatitis C virus (HCV) cure by direct-acting antiv
Externí odkaz:
https://doaj.org/article/ba95582a72194c988fc279a2ae9f097c
Autor:
Ryoichi Maenosono, Kohei Taniguchi, Takuya Tsujino, Hajime Hirano, Haruhito Azuma, Yuki Yoshikawa, Keita Nakamori, Yusuke Yano, Taizo Uchimoto, Tomohisa Matsunaga, Kazumasa Komura, Shin Egawa, Tomohito Tanaka, Hayahito Nomi, Yuya Fujiwara, Kazuhiro Takahashi, Kazuki Nishimura, Wataru Fukuokaya, Takeshi Tsutsumi, Teruo Inamoto, Kiyoshi Takahara, Takahiro Kimura, Hirofumi Uehara
Publikováno v:
Cancers, Vol 13, Iss 3554, p 3554 (2021)
Cancers
Volume 13
Issue 14
Cancers
Volume 13
Issue 14
Pembrolizumab has emerged as the new standard of care in patients with platinum-refractory metastatic urothelial carcinoma (mUC), whereas the optimal risk stratification to predict survival outcomes is still controversial. We examined a risk model fo
Autor:
Ryoichi Maenosono, Haruhito Azuma, Kazuhiro Takahashi, Keita Nakamori, Wataru Fukuokaya, Hajime Hirano, Hayahito Nomi, Shin Egawa, Hirofumi Uehara, Naokazu Ibuki, Kazuki Nishimura, Kiyoshi Takahara, Takeshi Tsutsumi, Tomohisa Matsunaga, Yuki Yoshikawa, Takuya Tsujino, Kohei Taniguchi, Kazumasa Komura, Taizo Uchimoto, Yuya Fujiwara, Tomohito Tanaka, Takahiro Kimura, Teruo Inamoto
Publikováno v:
Cancers
Volume 13
Issue 3
Cancers, Vol 13, Iss 526, p 526 (2021)
Volume 13
Issue 3
Cancers, Vol 13, Iss 526, p 526 (2021)
The identification of early or primary resistance to androgen signaling inhibitors (ASIs) is of great value for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the predictive value of prostate-specific a
Autor:
Hideyuki Nomura, Koichi Azuma, Toshimasa Koyanagi, Chie Morita, Akira Kawano, Aritsune Ooho, Hiromasa Amagase, Masaki Kato, Kazufumi Dohmen, Yasunori Ichiki, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Rie Sugimoto, Kazuhiro Takahashi, Kimihiko Yanagita, Shinji Shimoda, Masami Kuniyoshi, Takeaki Satoh, Makoto Nakamuta, Eiji Kajiwara
Publikováno v:
Cancers
Cancers, Vol 12, Iss 2602, p 2602 (2020)
Volume 12
Issue 9
Cancers, Vol 12, Iss 2602, p 2602 (2020)
Volume 12
Issue 9
Advanced fibrosis/cirrhosis and related biomarkers have been recognized as useful predictors of the development of hepatocellular carcinoma (HCC) by patients with chronic hepatitis C (CHC) following hepatitis C virus (HCV) cure by direct-acting antiv